1131-94-8

Basic information

• Product Name: 3-Hydroxy-4-methoxyphenylacetic acid
• Synonyms: HOMOISOVANILLIC ACID;3-HYDROXY-4-METHOXYPHENYLACETIC ACID;2-(3-hydroxy-4-methoxy-phenyl)acetic acid;Isohomovanillic acid;3-Hydroxy-4-methoxyphenylacetic acid ,98%;3-Hydroxy-4-Methoxybenzeneacetic Acid;4-Methoxy-3-hydroxyphenylacetic Acid;methyl 2-(3-hydroxy-4-methoxyphenyl)acetate
• CAS NO: 1131-94-8
• Molecular Formula: C9H10O4
• Molecular Weight: 182.17
• EINECS: 1312995-182-4
• Product Categories: Multisubstituted Benzene;Acids and Derivatives;Alcohols and Derivatives;Aromatic Phenylacetic Acids and Derivatives;Phenylacetic acid;API intermediates;Aromatics, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1131-94-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 128 °C
• Boiling Point: 371.3 °C at 760 mmHg
• Flash Point: 153.1 °C
• Appearance: /
• Density: 1.307 g/cm³
• Vapor Pressure: 3.59E-06mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.36±0.10(Predicted)
• CAS DataBase Reference: 3-Hydroxy-4-methoxyphenylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxy-4-methoxyphenylacetic acid(1131-94-8)
• EPA Substance Registry System: 3-Hydroxy-4-methoxyphenylacetic acid(1131-94-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1131-94-8(Hazardous Substances Data)

Usage

Chemical Properties

Pale Beige Solid

Uses

3-Hydroxy-4-methoxyphenylacetic acid is a 4-O-methylated metabolite of catechol amines in man. 3-Hydroxy-4-methoxyphenylacetic acid is also a metabolite of 3,4-dihydroxyphenylalanine (DOPA) analogues as well as a metabolite of Hydroxytyrosol (H977000).

Definition

ChEBI: A monocarboxylic acid that is the 4-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid.

Synthesis Reference(s)

The Journal of Organic Chemistry, 49, p. 2061, 1984 DOI: 10.1021/jo00185a061

InChI:InChI=1/C9H10O4/c1-13-8-3-2-6(4-7(8)10)5-9(11)12/h2-4,10H,5H2,1H3,(H,11,12)

Upstream product

• 73357-19-4 (5-hydroxy-4-methoxy-2-nitro-phenyl)-acetic acid 
• 70028-57-8 (3-hydroxy-4-methoxy-phenyl)-pyruvic acid 
• 7722-84-1 dihydrogen peroxide 
• 102-32-9 3,4-dihydroxyphenylacetate 
• 19626-36-9 methyl 2-(3-bromo-4-methoxyphenyl)acetate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 1699-39-4 2-(3-(benzyloxy)-4-methoxyphenyl)acetonitrile 
• 1699-38-3 3-benzyloxy-4-methoxy-benzyl chloride 
• 1860-60-2 3-benzyloxy-4-methoxy-benzyl alcohol 
• 6378-19-4 4-methoxy-3-nitrobenzyl chloride 
• 63304-80-3 (4-methoxy-3-nitrophenyl)acetic acid 
• 56245-07-9 2-(4-methoxy-3-nitrophenyl)acetonitrile 

Downstream Products

• 861323-48-0 (3-ethoxycarbonyloxy-4-methoxy-phenyl)-acetic acid 
• 21411-19-8 N-(β-4-hydroxy-3-methoxyphenethyl)-(3-hydroxy-4-methoxyphenyl)acetamide 
• 93279-67-5 4-Methoxy-3-((phenylsulfonyl)oxy)phenylacetic Acid 
• 23180-27-0 1-(3'-hydroxy-4'-methoxy-benzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 54186-35-5 1-(2-bromo-5-hydroxy-4-methoxy-benzyl)-1,3,4,7,8,8a-hexahydro-2H-isoquinolin-6-one 
• 54186-36-6 1-(2'-bromo-4'-methoxy-5'-hydroxybenzyl)-2-formyl-1,3,4,6,7,8-hexahydroisoquinolin-6-one 
• 74007-24-2 1-(2'-bromo-4'-methoxy-5'-hydroxybenzyl)-2-formyl-1,3,4,5,7,8-hexahydroisoquinolin-6-one 
• 74007-22-0 C₂₀H₂₅NO₅ 
• 74007-23-1 1-(2'-bromo-4'-methoxy-5'-hydroxybenzyl)-2-formyl-6-ketal-1,3,4,5,7,8-hexahydroisoquinoline 
• 74007-25-3 1-(2-Bromo-5-hydroxy-4-methoxy-benzyl)-1,3,4,5,7,8-hexahydro-2H-isoquinolin-6-one 
• 72258-91-4 1,2-dehydronorreticuline 
• 13168-51-9 N-benzoyl-norreticuline 
• 58116-06-6 (+/-)-6'-Bromo-N-norreticuline 
• 14199-16-7 (+)-Reticuline-Perchloric Acid 

Relevant articles and documents

One-Pot Biocatalytic In Vivo Methylation-Hydroamination of Bioderived Lignin Monomers to Generate a Key Precursor to L-DOPA

Electron-rich phenolic substrates can be derived from the depolymerisation of lignin feedstocks. Direct biotransformations of the hydroxycinnamic acid monomers obtained can be exploited to produce high-value chemicals, such as α-amino acids, however the reaction is often hampered by the chemical autooxidation in alkaline or harsh reaction media. Regioselective O-methyltransferases (OMTs) are ubiquitous enzymes in natural secondary metabolic pathways utilising an expensive co-substrate S-adenosyl-l-methionine (SAM) as the methylating reagent altering the physicochemical properties of the hydroxycinnamic acids. In this study, we engineered an OMT to accept a variety of electron-rich phenolic substrates, modified a commercial E. coli strain BL21 (DE3) to regenerate SAM in vivo, and combined it with an engineered ammonia lyase to partake in a one-pot, two whole cell enzyme cascade to produce the l-DOPA precursor l-veratrylglycine from lignin-derived ferulic acid.

COMPOUND AND AN ORGANIC SEMICONDUCTING LAYER, AN ORGANIC ELECTRONIC DEVICE AND A DISPLAY OR LIGHTING DEVICE COMPRISING THE SAME

The present invention relates to a compound having the formula (I); and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same.

Tetrahydropalmatine derivative and application thereof

The invention relates to a tetrahydropalmatine derivative and application thereof, a compound as shown in a formula (VI) and a preparation method thereof, and an application of the compound in medicine. Specifically, the invention relates to a derivative of the compound as shown in the general formula (VI) and a preparation method thereof, and an application of the derivative as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, diabetes type II, hyperglycemia, adiposis, or insulin resistance and metabolic syndrome. The compound disclosed by the invention also can reduce total cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides, and increases the expression of a liver LDL receptor and inhibits the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9).